Jazz Pharmaceuticals (NASDAQ:JAZZ) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report released on Thursday, Benzinga reports. They currently have a $140.00 price target on the specialty pharmaceutical company’s stock.

JAZZ has been the topic of a number of other reports. Wells Fargo & Company lowered their price objective on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an equal weight rating on the stock in a research report on Thursday. HC Wainwright reaffirmed a buy rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday. StockNews.com cut Jazz Pharmaceuticals from a strong-buy rating to a buy rating in a report on Friday, July 5th. Barclays cut their price objective on Jazz Pharmaceuticals from $230.00 to $200.00 and set an overweight rating for the company in a research report on Friday, May 3rd. Finally, Robert W. Baird decreased their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an outperform rating on the stock in a research report on Thursday. Four analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $175.20.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock traded down $1.39 during midday trading on Thursday, hitting $112.99. 215,045 shares of the company’s stock were exchanged, compared to its average volume of 682,730. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. The stock has a market cap of $7.13 billion, a price-to-earnings ratio of 23.40, a price-to-earnings-growth ratio of 1.70 and a beta of 0.58. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $146.70. The firm’s 50 day simple moving average is $107.68 and its 200 day simple moving average is $114.15.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.53 by ($1.55). Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.89%. The company had revenue of $901.98 million during the quarter, compared to analyst estimates of $938.99 million. Equities research analysts predict that Jazz Pharmaceuticals will post 15.31 EPS for the current year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently bought and sold shares of JAZZ. Vanguard Group Inc. raised its position in shares of Jazz Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock worth $776,551,000 after buying an additional 84,941 shares during the period. LSV Asset Management lifted its stake in shares of Jazz Pharmaceuticals by 1.6% during the first quarter. LSV Asset Management now owns 2,380,858 shares of the specialty pharmaceutical company’s stock worth $286,703,000 after purchasing an additional 37,631 shares in the last quarter. Polaris Capital Management LLC boosted its position in shares of Jazz Pharmaceuticals by 13.0% in the first quarter. Polaris Capital Management LLC now owns 1,432,660 shares of the specialty pharmaceutical company’s stock worth $172,521,000 after buying an additional 165,200 shares during the period. Capital World Investors acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at about $171,943,000. Finally, Swedbank AB purchased a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $106,936,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.